David Kirn
MD
Chief Medical Officer, Imvax Inc.
👥Biography 个人简介
David Kirn has been a pioneering figure in oncolytic virus clinical development for over two decades, including early work on ONYX-015 adenovirus and the poxvirus-based JX-594 (pexastimogene devacirepvec) in hepatocellular carcinoma. He has also developed the Imvax glioblastoma platform leveraging intratumoral antigen exposure for systemic vaccine induction. His career bridges the foundational clinical translation of oncolytic viruses from bench to bedside.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 David Kirn 的研究动态
Follow David Kirn's research updates
留下邮箱，当我们发布与 David Kirn（Imvax Inc.）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment